Item 7.01 Regulation FD Disclosure.
Oncternal's updated corporate slide presentation has been posted to the Company's website, www.oncternal.com. Oncternal plans to use its website to disseminate future updates to its corporate presentations and does not intend to file or furnish a Form 8-K alerting investors each time the presentation is updated.
The information set forth in this Item 7.01 is being furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, except as expressly provided by specific reference in such a filing.
By filing this Current Report on Form 8-K and furnishing the information in this
Item 7.01, Oncternal makes no admission as to the materiality of Item 7.01 in
this report or the presentation available on Oncternal's website. The
information contained in the presentation is summary information that is
intended to be considered in the context of Oncternal's filings with the
Cautionary Note Regarding Forward-Looking Statements
The Company cautions you that statements included in this report that are not a
description of historical facts are forward-looking statements. In some cases,
you can identify forward-looking statements by terms such as "may," "will,"
"should," "expect," "plan," "anticipate," "could," "intend," "target,"
"project," "contemplates," "believes," "estimates," "predicts," "potential" or
"continue" or the negatives of these terms or other similar expressions. These
statements are based on the Company's current beliefs and expectations. Forward
looking statements include statements regarding: the expected timing for
achieving key milestones, including completing and announcing results of
clinical trials of the Company's product candidates, and the anticipated market
potential, duration of patent coverage, and ability to obtain and maintain
favorable regulatory designations for the Company's product candidates and
preclinical programs. The inclusion of forward-looking statements should not be
regarded as a representation by the Company that any of its plans will be
achieved. Actual results may differ from those set forth in this release due to
the risks and uncertainties inherent in the Company's business, including,
without limitation: risks related to the failure to realize any value from
product candidates and preclinical programs being developed and anticipated to
be developed in light of inherent risks and difficulties involved in
successfully bringing product candidates to market; uncertainties associated
with the clinical development and process for obtaining regulatory approval of
Oncternal's product candidates, including potential delays in the commencement,
enrollment and completion of clinical trials; the risk that results seen in a
case study of one patient may not predict the results seen in other patients in
the clinical trial, including the possibility that there may not be additional
complete or sustained responses from any other patients in the study; the risk
that interim results of a clinical trial do not necessarily predict final
results and that one or more of the clinical outcomes may materially change as
patient enrollment continues, following more comprehensive reviews of the data,
as follow-up on the outcome of any particular patient continues, and as more
patient data become available; the risk that unforeseen adverse reactions or
side effects may occur in the course of developing and testing Oncternal's
product candidates; potential changes in the regulatory environment for
developing and obtaining approval of product candidates and preclinical
programs, which may result in delays or termination of development of such
product candidates or preclinical programs, or unexpected costs in obtaining
regulatory approvals; the risk that Oncternal may be unable to obtain sufficient
additional capital to continue to advance the development of its product
candidates and preclinical programs; and other risks described in the Company's
prior reports as well as in public periodic filings with the
2
--------------------------------------------------------------------------------
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. Exhibit No. Description 99.1 Updated Corporate Slide Presentation 3
--------------------------------------------------------------------------------
© Edgar Online, source